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ABSTRACT 
 
 The properties of nanoparticles play an important role in cellular uptake. In this study, 
we have investigated the effects of 14 arginine modifications on liposome characteristics 
such as size, zeta potential, the internalization of fluorescein with non-activated macrophages 
and changes in IC50 values on LPS-activated, IL-4 activated and non-activated macrophages. 
It is important to determine the influence of surface modifications of particle characteristics 
on internalization of different macrophages phenotypes. Here we demonstrated that modified 
surfaces impact particle internalization and this internalization is dependent on macrophage 
phenotype. Our data revealed that surface modifications alter the zeta potential and 
negligibly change particle size.  Internalization is tunable through alterations in zeta potential 
and hydrophobicity. These findings demonstrated that targeted drug delivery to macrophages 
could be achieved by exploiting material parameter.
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CHAPTER 1 
INTRODUCTION 
1.1 Targeted Drug Delivery 
     Drug delivery is a method or process of administering a pharmaceutical active 
compound to achieve a therapeutic effect in humans or animals1.   In modern society, 
nanoparticle drug delivery systems play important roles in cancer treatment.2 Cancer is 
already the second major cause of death in the US and the Agency for Healthcare research 
and Quality (AHRQ) estimates that the direct medical costs for cancer in the US in 2011 
were $88.7 billion.3There are more than one billion case diagnosed annually and around 
600,000  people will die from cancer this year, which is 1,600 deaths per day.3 The goal of 
targeted drug delivery is to release the maximum amount of medication at the site of injury or 
disease and reduce the drug distribution in the whole body, thus reducing or eliminating off-
target effects. To achieve this goal, the requirements for the drug delivery vehicle are: 1) a 
high drug loading capacity, 2) long circulation time, 3) appropriate release rates, and 4) non-
specific interaction with the host immune system. 4Nanoparticles coupled to ligands have the 
potential to achieve these requirements and be a “magic bullets”5 to shoot the desired sites. 
      Passive delivery is commonly used in the clinic for targeting tumor sites. Due to 
the larger pore size of blood vessels supplying tumors, aggressive tumors inherently develop 
leaky vasculature. Increased retention resulting from poor lymphatic drainage in tumors of 
nanoparticles and permeation within the tumor region allow extravasation to enhance drug 
delivery effects at the tumor site.6 This is called the enhanced permeability and retention 
(EPR) effect, which is the most common method of passive targeting. Tumor specificity is 
enhanced due to the differential accumulation of encapsulated nanoparticles, which is largely 
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influenced by particle size. Owing to the tight junctions of capillaries, passive targeting 
allows for increased drug concentration at the tumor site. 7  
     There are various factors that influence passive targeting. Size, surface properties, 
molecule weight, and polymer or particle fabrication method all impact tumor uptake. 
Hydrophobic particles around 200 nm have shown higher plasma resident time, which 
enhances the EPR effect.8 Many other factors have been reported from clinical studies such 
as surface charge, hydrophobicity, and immunogenicity 9 of the drug carriers; therefore, due 
to the complexity of the system, it is challenging to accurately predict material properties that 
will enhance tumor uptake.  
      To overcome the limitations of passive targeting, the idea of active targeting has 
been proposed, which involves the attachment of a ligand or molecule onto the surface of the 
drug delivery vehicle that can specifically bind to an overexpressed cell membrane receptor 
specific to the target cell.2 Identification of specific tumor biomarkers is crucial for efficient 
active targeting with limited off target effects resulting from expression of receptors on 
healthy cells. It has been reported that active targeting improves the therapeutic index to 
tumors in mice.10 The density of expressed targeted receptors on the cell surface is another 
determining factor for the success of active targeting. Increased specificity contributes to 
enhance antibody-mediated drug delivery, which is hindered by high cost and long 
production time.11  Liposomal doxorubicin (Doxil®) coupled with a growth factor 
overexpressed by a breast tumor (ErbB2) demonstrated a faster and shaper regression in 
tumor volume.12Anticancer monoclonal antibody 2C5 (mAb 2C5) with nucleosome-
restricted activity coupled with PEGylated Doxil remarkably improved accumulation in 
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Lewis lung carcinoma. Also, this targeted liposomal formulation enhances inhibition of 
tumor growth. 13 
     Liposomes are promising vehicles and have various advantages as drug delivery 
systems. It is important to design efficient systems and improve therapeutic efficacy. Both 
active and passive targeting are crucial methods by which to optimize efficiency, as well as 
other characters such as biodistribution, toxicity, and circulations time. 
1.2 Macrophages 
     Macrophages were the first described in 1884 and are a type of white blood cells, 
which differentiate from monotypes. 14 Macrophages are instrumental in both innate and 
adaptive immune responses .15 Depending on the type of stimulus that actives macrophages, 
the cells can exist on a spectrum of phenotypes, the ends of which are the pro-inflammatory 
or classical activated M1 macrophages and anti-inflammatory or alternatively activated M2 
macrophages. 16 M1 macrophages, also known as classically activated macrophages, are 
identified as CD64+CD80+ by flow cytometry.17 Macrophages can be polarized towards an 
M1 phenotype through interferon-γ (IFN-γ), lipopolysaccharide (LPS), tumor necrosis factor 
α (TNF-α), or monocyte chemoattractant protein-1 (MCP-1).18 Alternatively activated 
macrophages are CD11b+CD209+.17 Interleukin-4 (IL-4), IL-10, IL13, glucocorticoids, or 
vitamin D3 contribute to M2 functional polarization.19  
Macrophage internalization mechanisms are complex, and include macropinocytosis, 
endocytosis, and phagocytosis.20 Macropinocytosis is the major uptake pathway for 
extracellular fluids, solutes, macro- or small particles.21 Endocytosis is the general term to 
define the process for importing selected molecules, viruses, microorganisms, and nanometer 
sized particles. This process includes clathrin-dependent and independent receptor-mediated 
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endocytosis.22  Receptor-mediated endocytosis is the most effective mechanism for 
nanoparticle delivery to cells. 23  Ligands decorating the surface of the nanoparticle could 
bind to cell receptors, resulting in membrane invagination.79 Phagocytosis is a mechanism by 
which foreign particles such as dead cells, pathogens and digesting drug particles can enter 
cells. During the process of phagocytosis, the phagocyte-bound pathogen is surrounded by a 
phagocyte membrane and encapsulated in the phagosome, which is a membrane bound 
vesicle. 24 With the fusion of the phagosome and lysosome, the phagolysosomes digest 
internalized material.25  However, the process of lysis of pathogenic microorganism leads to 
the generation of other toxic composition such as NO, hydrogen peroxide, and superoxide 
anion, which damage the healthy host cells. 26 The response of a phagocyte to a target can be 
multilayered, which is shown in Fig 1.125 The responses of effective clearance of pathogenic 
microorganisms are: 1) surface receptors detect the microorganism and engulf and kill them 
and 2) internalized targets are presented as antigens to T cells. 25 
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Figure1.1 Information processing at different stages of phagocytosis 25 As phagocytosis 
proceeds from the initial binding of a target to actin-dependent internalization and ultimately 
to degradation of the target in the phagolysosome, myeloid cells acquire information about 
the target through a variety of mechanisms. At the cell surface, receptors sample the chemical 
constituents of the particle and membrane dynamics facilitate an assessment of its physical 
properties. Additional information is gathered as the phagosome pinches off from the plasma 
membrane and as it matures through interactions with other intracellular compartments. 
Finally, the degradation of the target exposes ligands that were not previously accessible and 
releases ligands into the cytosol for detection by intracellular receptors. The information 
gathered by all of these processes is integrated to shape the ensuing immune response. 
 
Although more receptors need to be identified, some receptors have been definitively 
shown to be mediate phagocytosis. Fc receptors could be used to recognize antibody-
opsonized particles and initiate numerous signal pathways through two subtype receptors: 
activation receptors and inhibitory receptors.27  However, most targets engage several 
receptors on the phagocytes’ surface, making it hard to define the exact role of the individual 
receptors in internalization.  
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Macrophage reprograming plays an important role in cancer treatment and can offer 
potential antitumor activities. For health bodies, macrophages are a kind of protector, 
producing inflammatory mediators (cytokines and reactive oxygen species) and activating 
adaptive immune cells. 28 In the early stages of tumor growth, large quantities of 
inflammatory mediators are produced and a cancer-related inflammatory microenvironment 
is generated, 29 inducing tumor cell proliferation or genetic instabilities in the healthy cells. 
The early tumor development stage is characterized by an M1-like polarized inflammatory 
environment. 28 Production of IL-10, low levels of inflammatory cytokines, and reactive 
oxygen intermediates, along with poor antigen expressing abilities are characteristic of 
macrophages in mature tumors, which are considered to adopt a more M2-like phenotype. 
These cells are termed as tumor associated macrophages (TAMs).  Thus, cancer could be 
considered a disease that is promoted by the permissive environment created by 
macrophages. Reprogramming the macrophages, from TAMs to M1-like phenotype, is a 
promising method to develop anti-tumor therapies. 
1.3 Liposomes 
Since the 1960s liposomes have been described and used as drug delivery vehicles for 
chemotherapeutics in cancer therapy. 2 Currently, liposomes are one of the most widely 
investigated drug delivery systems and are used in the clinic. 30,31 Seventeen liposomal drug 
formulations have been clinically approved and many more are in clinical trials. 32,33  
Solutes carried by liposomes been extended to chelating agents 34, antibiotics 35, hormones36 , 
proteins 37, and anti-tumor drugs. 38 
Liposomes are artificially prepared spherical vesicles composed of a lamella phase 
lipid bilayer. The spherical structure allows liposomes to encapsulate a variety of types of 
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materials – both hydrophobic and hydrophilic drugs – within either the phospholipid bilayer 
or within the internal aqueous core, which makes them attractive drug delivery vehicles. 
Size, surface polymeric coating, and surface charge are significant factors that 
influence the biological activates of liposomes. The size of liposome determines the 
biodistribution of the particles – in tumor vasculature or tumor interstitial space. For 
liposomes that passively target to the tumor site, liposomes are typically less than 200 nm in 
diameter. 8 Liposome can be coupled with active targeting ligands on their surfaces, releasing 
their payload near or within the tumor microenvironment. For larger particles, liposomes 
release the drugs within tumor capillaries. 39 Surface polymeric coatings enhance the stability 
of the particles and their resistance to clearance. 40 Polyetheylene glycol (PEG) is the most 
widely used polymer in liposomal drug delivery systems. PEG coated liposomal doxorubicin 
formulation has a half-life of 45 h 41 while non-PEG coated liposomes have a 2-3 h half-life. 
Surface charge is another factor that influences the clearance kinetics. Due to the effective 
process of ionic mediated interactions, cationic liposomes are widely used as DNA delivery. 
42 Negatively and positively charged particles are taken up by cells to a larger extent than 
neutral particles.3 Cationic liposomes are associated with efficient cellular delivery of drug 
cargoes and are routinely used in in vitro gene delivery applications. The positive charge 
particles have stronger electrostatic interactions with negatively charged cell membranes to 
enhance cell uptake.43  
As a nanocarrier, surface modification involving various ligands impact the 
internalization of liposomes by cancer cells, Fig 1.2 shows the process of surface ligands 
target a cancer cell. The surface ligands promote the targeting efficiency and enhance the 
effects of cancer cell uptake drug. Liposomes coupled with triple-helical “peptide-
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amphiphiles” (R1 (IV) 1263-1277 PA) exhibit increased stability compared to DPPC 
(dipalmitoylphosphatidylcholine) liposomal systems and have a higher loading capacity 
compare to unmodified liposomes. 12 Peptide HVGGSSV conjugated to liposomal 
doxorubicin has remarkable targeting ability and heightened cytotoxic effects. 44 Anti-HER2 
PEGylated liposomes are preferentially internalized in HER2+ breast cancer HER2 compared 
to non-targeted liposomal formulation. 45 
 
Figure1.2 Schematic depicting a liposome generated using phospholipids, followed by 
a liposome surface modified to contain a targeting ligand specific for upregulated cell surface 
receptors present on a cancer cell. 2 
 
Liposomes have been chosen as a therapeutic carrier owing to its advantages of: 
biocompatibility, preventing premature degradation of encapsulated cargo, entrapment of 
both hydrophilic and hydrophobic drugs, targeted delivery, site avoidance, and size and 
composition based tunable biodistribution.46 Liposome structures are shown in Fig1.3. 
However, the major limitation of liposomes is the fast elimination from the blood steam and 
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recognition by the reticuloendothelial system.47 Plasma proteins rapidly adsorb to liposomes 
and they can be eliminated through the mononuclear phagocytic system. Surface membranes 
coat with protein in a short time, which reduces the circulation time in blood. 48, 80  
 
Figure1.3 The schematic representation of the structure of liposome 46 
      Petros et al. 49 proposed that modifying the surface of liposomes with dysopsonins 
reduces recognition from complement components, such as the membrane attack complexes 
and inhibits phagocytosis from macrophages, neutrophils, and monocytes. Stealth liposomes 
have been coated with polymers to extend the circulation time such as PEG 41, poly(vinyl 
pyrrolidone) (PVP) 50, and amphiphilic polyacrylamide. 51The blood circulation time has 
been increased and stability enhanced through these modifications. Combinatorial 
approaches have been utilized to extend circulation time of liposomes and improve targeted 
delivery of drug loaded liposomes through synergy. Xiong et al. 52 demonstrated that 
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doxorubicin encapsulated in RGD-modified PEGylated liposomes have higher splenic uptake 
and more effective inhibition in tumor growth than sterically stabilized liposomes 
encapsulating doxorubicin, while both formulations contribute to prolonged circulation time 
sand increased tumor accumulation. Cationic liposomes with PEG provide a greater colloidal 
stability of particles to enhance the circulation time and a lower zeta potential to prevent non-
specific lung delivery. 42 
The US Food and Drug Administration (FDA) has approved diverse liposome 
formulations of the encapsulation of tumor therapeutic drugs. Liposomal formulations of 
doxorubicin have been developed for cancer treatment, which reduced cardiotoxic side 
effects and increased the therapeutic effects on the tumor.  Doxil® was the first approved 
liposome formulation doxorubicin (Ben Venue Laboratories, Inc Bedford, OH) for 
chemotherapeutic treatment of refractory acquired immune deficiency syndrome (AIDS)-
related Kaposi’s sarcoma. 53 Doxil® was the first generation of liposomal doxorubicin and 
reduces cardiotoxicity, neutropenia, vomiting, and alopecia. 53 Lipo-dox® (TTY Biopharm 
Company Ltd, Taipei Taiwan) is the second generation and prolongs the circulation half-time 
to 65 h. 53 The third and latest generation is ThermoDox® (Celsion  
Corporation,Lawrenceville, NJ), a thermosensitive liposomes, which releases entrapped 
drugs in the targeted area where the tissue temperature is evaluated. 54 
Liposomes are not only promising nanoparticle vehicles, but also have proven clinical 
success. Liposomes can be used to passively targeting cancer for treatment with 
chemotherapeutics. A growing number of studies are focusing on liposomes with surface 
modifications with targeting ligands and multiple functionalities, which could enhance the 
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internalization of chemotherapeutics by cancer cells, raise the rate of uptake of drugs, and 
control drug release.  
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CHAPTER 2 
 
THE EFFECT OF MACROPHAGE PHENOTYPE AND SURFACE MODIFICATION OF 
LIPOSOMES ON INTERNALIZATION 
 
 
The effects of surface modifications on liposomes using a library of arginine 
derivatives for improved drug delivery were examined.  Encapsulating either fluorescein or 
doxorubicin, both unmodified liposome and modified liposomes were tested for their drug 
delivery properties and propensity for internalization with macrophages. The modified 
liposomes were characterized by dynamic light scattering (DLS) and zeta potential. The 
resulting liposomes were able to encapsulate doxorubicin with a loading efficiency greater 
than 90% and cumulative releases of less than 15% after 144 h.  The internalization of these 
particles was examined by loading the liposomes with fluorescein or doxorubicin to test 
internalization through fluorescence level and half maximal inhibitory concentration (IC50), 
respectively. Macrophages were activated with LPS or IL-4 to induce M1- or M2-like 
phenotypes. Naïve macrophages were also studied. Most modified liposomes enhanced the 
cytotoxicity of doxorubicin compared to unmodified liposomes. Macrophage phenotype was 
also observed to influence the cytotoxicity of the modified liposomes, with some modified 
liposomes enhancing the cytotoxicity in LPS stimulated macrophages and some enhancing 
IL-4 stimulated cells. 
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2.1 Introduction 
 Liposomes have been extensively used as biocompatible and biodegradable 
nanocarriers for a variety of applications extending from basic research to clinical uses. 
Currently, there are 17 different liposomal formulations that have been approved by US Food 
and Drug Administration (FDA) for clinical treatments and a large number of formulations 
are in clinical trials. 32 Doxil®, the first FDA approved liposomal formulation, was initially 
approved in 1995 for use in treatment of Kaposi’s sarcoma. 55 DaunoXome®, a liposomal 
formulation daunorubicin, is in use as treatment of leukemia and blood tumors. Clinical 
reports have demonstrated that DaunoXome® results in less alopecia and neuropathy and 
tumor uptake is 10-fold higher compared to free drug. 53. Compared to other nanoparticles, 
such as micelles, liposomes are unilamellar lipid bilayer nanoparticles and are larger than 
micelles, providing less drug leakage and enhanced encapsulation capability. 2 Liposomes are 
commonly delivered to tumor sites through passive targeting, exploiting the enhanced 
permeation and retention (EPR) effects of the tumor. 56 Liposomes also have the potential to 
actively target tumors through the tumor cell specific or maker targeting. PE38KDEL-loaded 
anti-HER2 PEGylated liposomes, possessing receptor-specific binding for HER2-
overexpressing SK-BR3 cells, have shown more cytotoxic effects than non-targeted 
PEGylated liposomes. 45. H2009.1 specific peptide conjugated to liposomal doxorubicin 
exploits multivalent peptides and liposomes to increase targeting to αvβvi. 57 
Targeting drugs to macrophages have been reported through many methods, most of 
which are achieved through liposomes. 58,59  Macrophages change their phenotype due to the 
stimulus that activates macrophages. Pro-inflammatory or classical activated M1 
macrophages 16 could be activated with interferon (IFN)-γ or lipopolysaccharide (LPS), while 
14 
 
 
anti-inflammatory or alternatively activated M2 macrophages could be activated by 
interleukin (IL)-4. 17 To more accurately describe the phenotype of the macrophages in vitro, 
the new nomenclature proposed by Murray et al. 60 will be used throughout the paper, which 
is based on the molecule used to activate the cells, for example M(LPS) and M(IL-4). Naïve 
cells will be denoted M (0). The plasticity of macrophages provides potential for macrophage 
reprogramming to synergistically act with chemotherapeutics. Tumor associated 
macrophages (TAMs) represent a subset of M2 macrophages, which can be reprogrammed 
cytotoxic M1 macrophages to prevent tumor growth. It has been reported that oligomannose-
coated liposomes encapsulating 5-fluorourracil successfully controlled tumor growth via 
macrophages as cellular vehicles. 61 
Arginine plays an important role in immune responses, which is metabolized by two 
enzymes differently up-regulated in polarized macrophages: 18,62 nitric oxide synthase (NOS) 
and arginase. The former produces citrulline and reactive nitrogen intermediates in M1 
macrophages, and the latter produces ornithine and urea in M2 macrophages. 18 Some 
arginine derivatives have been investigated and have shown therapeutic effects. Nitroarginine 
has neuroprotective effects in Alzheimer’ disease, Parkinson’s disease, and AIDS. 63 
Acetylcarnitine, involved in membrane stabilization and repair, reduces protein oxidation and 
toxic fatty acid ethyl esters in different organs. 64 
 In this study, we fabricated liposomes and modified their surfaces with 14 molecules 
chemically similar to arginine to investigate the effects of surface modifications on 
internalization by non-active macrophages. Also, we characterized the size and surface 
charge of both modified and unmodified liposomes. Finally, the liposomes were loaded with 
doxorubicin, an anti-cancer drug, and were examined for their loading efficiency and release 
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kinetics at pH 7.4. Changes in the IC50 of doxorubicin entrapped in the unmodified and 
modified liposomes was compared to that of free doxorubicin in M (LPS), M(IL-4), and 
M(0) macrophages.  
 
2.2 Material And Methods 
All materials were purchased through Sigma and were used as received, unless 
otherwise stated. Fresh deionized water (Milli-Q, Thermo Scientific Nanopure, Waltham, 
MA) was used throughout this study. Error bars indicated the standard deviation.  
2.2.1 Liposome particle modification  
In a 250 ml round-bottom flask, 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE, Avanti Polar Lipids, Inc., Alabaster, AL) (87.5mg) and 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC, Avanti Polar Lipids, Inc.) (43.75mg) were dissolved in chloroform 
(15.75 ml) and rotary evaporated at 40°C for 5 mins. Then, the lipids were mixed in 15 ml 
phosphate buffered saline. (PBS, diluted from 10× solution to 0.1 M, pH 7.4, Fisher 
Scientific, Pittsburgh, PA) After dialyzing against Milli-Q water overnight, the liposome 
particles are freeze-dried by a lyophilizer (Labconco, 4.5L, Kansas City, MO). Fourteen 
different molecules (Figure2.1) were used to modify the liposomes. In a vial, 2 ml PBS, 10 
mg/ml of lyophilized liposomes resuspended in PBS, 2 mg surface modifier, and 20 mg N-
(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) were stirred overnight. 
This process repeated for all 14 surface modifiers. The particles were dialyzed overnight 
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against Milli-Q water and lyophilized. 
 
Figure2.1 Chemical structures of molecules used for the modification of liposomal particles. 
The arginine derivatives shown here are lettered for easier identification in experiments and 
discussion throughout the chapter. 
 
 
2.2.2 Zeta potential and dynamic light scattering 
Milli-Q water was adjusted to pH 7 with HCl or NaOH to ensure the ions in the water 
would not influence the results by interference with the liposomes. To 5 ml H2O, 100 μl 1% 
w/v of particles were added and extruded through 100 nm polycarbonate membranes using 
an Avanti Mini-Extruder manual extruder (Avanti Polar Lipids, Inc.) 5 times for all 14 
modified liposomes and unmodified liposomes. Zeta potential and particle size was measured 
with a Zetasizer Nano Z (Malvern).  
2.2.3 Fluorescent particles and cellular uptake 
To measure internalization of the liposomes by macrophages, 2mg of liposome 
particles were mixed with 1 ml FC (Fluorescein, 1 mg/mL in acetone). The liposomes were 
subsequently dried at 55 ℃ for 4 h and particles were resuspended in 2 ml PBS. The 
liposomal suspension was passed through a Sephadex G-50 column (Fisher Scientific) to 
remove the unencapsulated FC. RAW 264.7 cells (ATCC, Manassas, VA) were cultured at 
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37 ℃ with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM high glucose; Thermo 
Scientific) supplemented with 10% fetal bovine serum, 100 U/L penicillin, and 100 μg/L 
streptomycin to be referred to as complete media (CM). Cells (50,000 cells/well with 100 µL 
of media in each well, except negative control) were seeded in a black 96 well plate. After 
incubating for 24 h at 37°C, the media was carefully aspirated and then 200 µL liposomes 
resuspended in CM were added to the wells. These cells were either incubated at 37°C to 
measure internalization of the liposomes, or at 4°C for cold binding experiments. 
To measure internalization of the particles, the cells were further incubated at 37°C 
for 4 h, the media aspirated, and 100 µL 0.25% trypan blue (Corning, Manassas,VA) was 
added to quench the extracellular fluorescence. The trypan blue was aspirated after 1 min and 
the fluorescence was measured at an excitation of 360 nm and an emission of 460 nm using a 
plate reader (BioTek Synergy HT Multidetection Microplate Reader, Winooski, VT). 
Cold binding experiments were performed by incubating at 4°C for 4 h, aspirating the 
media, washing the plate with sterile PBS, and quenching with 100 μl  0.25% (w/v) trypan 
blue. The fluorescence was measured at 360/460 nm with the plate reader. Controls for both 
internalization and cold binding experiments consisted of the above experiments without 
cells and the above experiments without liposomes. Ten replicates were obtained for all 
modified liposomes. 
2.2.4 Drug loading and release 
Doxorubicin was used as a model drug for liposome loading and release. In 2 ml 
critic acid (150 nM, pH 4), 10 mg modified or unmodified liposome from section 2 was 
suspended and extruded 21 times using an Avanti Mini-Extruder manual extruder. The 
liposomes were neutralized to pH 7.4 with NaOH or HCl. Both doxorubicin solution (PBS, 
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10 mg/ml) and the extruded liposomes were heated to 65℃ for 10 minutes. Subsequently, 
200 µl doxorubicin was added to the suspended liposomes and incubated at 65℃ for 45 
minutes. The liposomes were centrifuged at 3000 rpm for 5 minutes and the supernatant was 
removed. To a 96 well plate, 50 µL of supernatant removed from the liposomes and 50 µL of 
PBS were added into each well. A standard curve was made through a serial dilution of 
1mg/ml doxorubicin. The amount of unentrapped doxorubicin was analyzed by measuring 
the absorbance at 490 nm with a reference at 630 nm using a plate reader. Loading efficiency 
of the liposomes was calculated by  
       (1) 
where Csup is the concentration of doxorubicin in the supernatant and Ctotal is the 
concentration of doxorubicin added to the liposomes. 
Liposomes loaded with doxorubicin were placed in a dialysis membrane, and placed 
in a beaker with 100 mL of PBS. The beaker was sealed and incubated at 37 ℃. Aliquots of 
1 ml were collected periodically and assayed spectrophotometrically with a plate reader at an 
absorbance of 490 nm with a reference at 630 nm. After sample was removed, 1 ml PBS was 
added to maintain a constant volume.  
2.2.5 IC50 
RAW 264.7 cells (50,000 cells/well in 100 μL CM in every well except the negative 
control) were seeded into a 96 well plate for 24 h. A serial dilution of liposomes loaded with 
doxorubicin was added to the plate. A positive control was conducted without particles. After 
incubating for 48 h at 37°C, the media was aspirated and 10 μL of 5 mg/mL methyl thiazol 
tetrazolium (MTT) and 100 μL CM were added to each well. The plate was incubated at 
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37°C for 2 h. A volume of 85 μL was aspirated from each well and 100 μL DMSO were 
added to dissolve the insoluble formazan crystals. The optical density at 540 nm and a 
reference of 690 nm were measured with a plate reader. Data was normalized to cells 
cultured without particles and 6 replicates were obtained for each experiment. 
2.2.6 Statistics and data analysis 
Statistical analysis was performed using XLSTAT statistical software. Statistical 
significance of the mean comparisons was determined by ANOVA. Differences were 
considered statistically significant for p < 0.05. 
 
2.3 Results 
2.3.1. Liposome characterization 
Subtle differences between the different modifiers were reflected in zeta potential 
values derived from the electrophoretic mobility measurements under identical experimental 
conditions.2  Zeta potential represents the relative surface charge of particles, which 
contributes to particle internalization. 1  Fig2.2 A shows the zeta potential of both modified 
and unmodified liposomes. Unmodified liposome have a zeta potential of -16.8 ± 0.8 mV， 
which is similar of other reports.65,66 All modified liposomes were negatively charge over a 
wide range (from -8.9 to -33.9 mV), which may arise from the different functional groups of 
the modifiers.  
Nanoparticle size is a determining factor in drug delivery.1 Through dynamic light 
scattering, the diameter of the nanoparticles was measured (Fig2.2 B).  The unmodified 
liposome was found to be 96.3 ± 9.4 nm and the size of modified liposomes was measured to 
be ~100 nm, with the largest liposome being 108.8 ± 14.8 nm. The size of the unmodified 
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liposome matches the previous reports. 67,66 The polydispersity index (PDI) ranged from 
0.096 to 0.167 for all of the particles.  
 
2.3.2. Drug loading and release  
A transmembrane pH gradient was employed as an active loading method to 
encapsulate doxorubicin in liposomes. 31 Through drug self-association and interaction with 
salts, doxorubicin precipitates  
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Figure2.2  Material characterization of modified liposome particles. (A) Zeta potential and 
(B) DLS measurements of the liposomes. Both measurements represent three replicates for 
each sample, all data are shown by mean value ± standard deviation. 
 
in the aqueous core of liposome. 30 It is a direct method to encapsulate doxorubicin to 
achieve optimum efficiency and reduce costs. The loading efficiency (Fig2.3) shows that all 
liposomes have a loading efficiency of greater than 90%. Liposomes loaded with doxorubicin 
were incubated in PBS (pH 7.4) at 37 °C for 144 h to monitor drug release using the dialysis 
bag method. All of the liposomes released less than 15% of encapsulated doxorubicin after 
144 h, as shown in Fig 2.4, which indicates sustained release capability. Modification D has a 
lower release percentage compared to the unmodified liposome (p < 0.05). According to the 
B 
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statistical analysis, there are no differences among the modified and unmodified liposomes (p 
> 0.05), indicating a uniform encapsulation capability. 
 
 
2.3.3. Particle internalization 
The unmodified and modified liposomes were loaded with FC and were incubated 
with RAW 264.7 macrophages to measure particle internalization. A constant particle 
concentration (0.1mg/ml) was used throughout the study. After incubation with the cells, the 
fluorescence of FC was quenched with trypan blue. Fig 2.5 shows the fluorescence level of 
particle internalized with the macrophages. At 4 °C, all pathways for cell internalization are 
blocked. 68 The lack of fluorescence indicates that there is very little particle internalization 
or adsorption on the cell surface at 4 °C. At 37 °C there is a substantial increase in the 
fluorescence level, which demonstrates that the liposomes are internalized by the 
macrophages. The highest fluorescence value is for modification N, which is around 4 fold 
greater than the lowest modification, M.  Particles A, C, D, G, H, K, and M are statistically 
similar to unmodified liposomes (p > 0.05) with all other modifications more favorably 
internalized compared to unmodified liposomes (p < 0.05). 
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Figure2.3 Doxorubicin loading efficiency for unmodified and modified liposomes. 
Measurements represent three replicates for each sample; all data are shown by mean value ± 
standard deviation. 
 
2.3.4. IC50 
IC50 is the half of maximum of inhibitor concentration, which is a measurement of the 
cytotoxic effects of liposomal delivery of doxorubicin. Macrophages stimulated with LPS or 
IL-4, along with naïve macrophages were incubated with the doxorubicin loaded liposomes 
for 48 h and their responses was calculated as a percentage of the cells not treated with the 
liposomes. 14 Sigmoidal dose-response curves were used to calculate IC 50 for each 
macrophage condition and liposome modification, shown in equation 1: 
24 
 
 
      (1) 
Where  is the upper limit of the dose curve, is the lower limit, is the IC50, 
and  is the steepness of the curve. M (LPS), M (IL-4), and M (0) macrophages were tested 
(Fig2.6).  
 
 Figure2.4 Cumulative doxorubicin release from modified and unmodified liposomes at 144 
h incubation in PBS. 
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Figure2.5 Fluorescence level of FC loaded particles incubated with macrophages. Data 
presents the mean value of ten replicates for each sample ± standard deviation. 
 
And according to Fig 2.6, surface modifications contribute to sharply decrease of IC50 
compare to unmodified liposome for all macrophage phenotypes. Unmodified liposome has 
similar IC50 levels for M (IL-4) and M (0) and lower IC50 values for M (LPS). Lower IC50 
values indicate higher cytotoxicity. 
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Figure2.6 IC 50 concentrations and dose-response curve by LPS or IL-4 or non-activated 
macrophages. (A) IC50’s for modified liposomes, unmodified liposome loaded with 
doxorubicin and free doxorubicin by LPS or IL-4 activated or naïve macrophages. Data 
represents the mean value of three replicates for each sample ±standard deviation. (B) Dose-
response curves for free doxorubicin, doxorubicin loaded in unmodified liposome and 
doxorubicin loaded in liposome G after incubating 48 h in the presence of IL-4 activated 
macrophages. Data represents the mean value of five replicates for each sample ±standard 
deviation.  
 
Fig 2.6A and B show the IC50 and dose-response curves of modified liposome loaded with 
doxorubicin. For LPS activated macrophages, most of the liposomal doxorubicin 
formulations have more acute activity compared to the unmodified liposome (IC 50 <10 
μg/ml). For IL-4 activated macrophages, unmodified liposome and modifications A, B, and C 
show weaker activities than unmodified liposomes, with IC50 values of 24.6, 25.5, 27.3, and 
B 
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32.6 μg/ml, respectively, while modifications E through N show comparably acuter effects. 
Naïve macrophages exhibited higher IC50 in the presence of unmodified liposomes and 
modifications A and N compared to the modified liposomes (p < 0.05). All tested particles 
display a high toxicity, with the highest being modification C in the presence of IL-4 
activated macrophages (IC50= 32.6 μg/ml). From Fig2.6 IC50 values for most modifications 
were lower for LPS-activated macrophages than IL-4 activated macrophages, with the 
exception of modifications H and I and negligible differences between the two phenotypes 
for modification E.  From the activated and non-activated data it could be concluded that 
doxorubicin loaded in modified liposomes alters the IC50 depending on the stimulation of 
macrophages and can be exploited to improve drug delivery. 
 
2.4 Discussion 
2.4.1 Liposome properties influenced by surface modification 
It has been reported that liposome size and surface charge have a significant effect on 
potential targeting and encapsulation capability. 67,69 Modifications with the arginine 
derivatives in Fig 2.1 on the liposomes result in changes to the surface charge of liposomes. 
Unmodified and all of the modified liposomes explored here are negatively charged, which 
has been reported to have higher association effects with cells and more efficient delivery 
than neutral liposomes when encapsulating methotrexate-γ-aspartate. 58  Previous studies 
have reported that the extent of phagocytosis increases with increasing zeta potential, both 
negative and positive, and was lowest when the zeta potential was zero.58  Several similarities 
between alterations in the zeta potential value and internalization with FC and IC50 values of 
encapsulated doxorubicin were observed. In internalization with FC, with the exceptions of 
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modifications B, F, J, and N, the internalization of the particles follows the zeta potential 
with more negative liposome surface charges corresponding to higher FC uptake. In the IC50 
test, M(0) macrophages have increasing cytotoxicity with more negative zeta potential except 
in the case of medications C, G, H, I, and L. Attachment of liposomes to cell membranes is 
the first step of internalization, which is affected on surface changes of particles .70 It has 
been suggested that there are cationic binding sites on cell surfaces that promote formation of 
clusters of negatively particles, owing to the repulsive interactions of the cell lipid membrane, 
thus improving internalization of negatively charged particles. 70 It is well known that 
charged particles become opsonized and enter cells through absorptive endocytosis. 71 Many 
positively charged liposomes exert toxic effects on cells, thus making negatively charged 
liposomes, such as those studied here, a more attractive carrier for drug delivery. 
There were no significant differences in size between unmodified and modified 
liposomes after extrusion through 100 nm membranes, which provides uniform diameters 
and volumes. It has been reported that extrusion of liposomes could enhance the entrapment 
capability. 56 Small particle size (<200nm) is also known to enhance drug accumulation at the 
tumor site. 72 The high retention of doxorubicin in these liposomes demonstrates the strong 
and similar stability of particles due to the uniform liposome size (~100 nm), which has 
previously been demonstrated as a factor in high drug retention levels in liposomes. 67The 
loading efficiency showed no significant differences across the library of modified liposomes. 
Size has been reported in many studies 52,45,73 as a crucial factor in altering pharmacokinetics 
due to the impact on tissue distribution and clearance. 45 These particles were kept around 
100 nm to eliminate variables in characterizing drug release profiles and interactions with 
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cells. Taken all together, liposomal modifications with arginine derivatives have little 
influence on their size and drug loading ability. 
2.4.2 Influence of macrophage phenotype on internalization and the efficacy of 
         delivered doxorubicin   
 
Macrophages play important roles in creating a permissive environment for tumors, 
thus targeting drugs to macrophages is an efficient method for drug delivery.58 Targeting 
doxorubicin encapsulated in liposomes to macrophages is a method of improving the current 
passive targeting typically used with Doxil®, and increasing intracellular uptake is the main 
purpose for the future in vivo study. Doxorubicin is a widely and commonly used drug for 
cancer treatment. Doxorubicin can intercalate between DNA base pairs, which inhibits DNA 
and DNA-dependent RNA synthesis by template disordering and steric obstruction. 74 
Another special character of doxorubicin is inducing the formation of covalent 
topoisomerase-DNA complex. When copying DNA, this capability could inhibit the 
religation portion of the ligation-religation reaction. Although doxorubicin contributions to 
the inhibition of tumor growth, cardiac toxicity is its main limitation. To ameliorate off-target 
effects, one effective approach is modifying the drug carrier, which could change the 
biodistribution of doxorubicin, leading to reduce the levels of the drug in healthy tissue.   
Cell viability data shown in Fig 2.7 demonstrated cytocompatibility after 4 h 
incubation for both unmodified and modified particles. For LPS activated, IL-4 activated, 
and M(0) macrophages, viabilities are generally above 80%, indicating low toxicity of the 
particles. The phagocytic process of liposomes by macrophages starts with surface 
projections of lamellipodia, resulting from filaments. The lamellipodia become pseudopodia 
as cytoplasm flows into the lamellipodia, which allows the cell to engulf particulate. 58 The 
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complex steps of internalization between liposome and macrophage are 1) stable adsorption 
to the cell surface; 2) cellular uptake of intact vehicles; and 3) lysosomal degradation of the 
liposomes and their content. 
 
 
  
Figure2.7 Viability assay showing the cytotoxicity of all particles on LPS or IL-4 activated 
or non-activated RAW 264.7 cells. (Data represents the mean value of five replicates for each 
sample± standard deviation) (Taken from Hannah Bygd.) 
 
Several mechanisms for endosomal escape have been proposed. The proton sponge 
effects, also known as the pH-buffering effect, is mediated by agents with a high buffering 
capacity and the flexibility to swell when protonated. 75 An extensive inflow of ions and 
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water induced by protonation into endosomal environment, results in cracking of the 
endosomal membrane and releasing the encapsulated contents. Poly (amido amine) s, which 
have protonated amine groups in their structure, contribute to a high buffer effect which 
results in increases in the osmotic pressure of the endosome and disrupts the endosomal 
membrane. 76 The flip-flop mechanism involves exchange of the liposomes in the endosomal 
wall and the delivered liposome, resulting in endosomal escape into cytosol. 77 Due to the 
electrostatic interaction between the cationic lipoplexes and the negatively charged lipids of 
the endosomal membrane, anionic lipids diffuse into the lipoplexes and form charge-
neutralized ion pairs with cationic lipids. 78  Membrane fusion is the destabilization of the 
endosomal membrane due to fusogenic peptides, which is a significant process in cellular 
delivery and endocytosis. Haemeagglutin subnit HA2 of influenza virus change conformation 
when inside the endosomes due to the low pH environment and the highly conserved 
hydrophobic N-terminal region.  This viral membrane fusion results in viral genome leakage 
to cytosol. 79 When liposomes interact with macrophages, the encapsulated drugs are taken 
by diffusing out of vehicles or directly “eaten” through lysosomal degradation. Escape from 
the liposome depends on the drug release rate from liposomes and macrophage permeability 
to the drugs. 52 
       Figure 2.6A shows the IC50 values of modified liposomes on M(LPS), M(IL-4), and 
M(0) macrophages. The influence of polarization indicates macrophage phenotype is 
significant for internalizing liposomes. Lower IC50 levels demonstrate more acute activities 
of doxorubicin resulting from particle interactions with the cells. The different uptake levels 
may be influenced by different pathways for the different phenotypes. 28 From Fig 2.6 it is 
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obvious that M (LPS) have lower IC50 values, with the exception of modifications H and I, 
compared to M (IL-4) cells.  
Although the internalization mechanisms of macrophages are complex, the results 
provides some clues to predict which modifications can be exploited to enhance toxicity of 
doxorubicin or improve selective delivery to specific macrophage phenotypes. The trends 
between the IC50 values of doxorubicin and internalization measured through entrapped FC 
exhibit many similarities. Internalization of FC loaded modifications are generally higher 
than unmodified liposome with the exception of modifications A, G, H, and M. Modification 
N is even four fold higher than unmodified liposome. In examining the IC50 values, the 
toxicity of doxorubicin is enhanced compared to unmodified liposomes with a few 
exceptions. For LPS activated macrophages, only modifications A and N are higher than 
unmodified liposomes (p < 0.05), while modification H and I are similar to unmodified 
liposomes. For IL-4 activated macrophages, modifications A, B, and C are higher than 
unmodified liposomes (p < 0.05). For non-activated macrophages, none of modifications are 
higher than unmodified liposomes. Thus, it is obvious that modifications to liposomes can 
enhance the cytotoxicity of encapsulated drugs. One possible explanation of difference 
between internalization of FC loaded liposomes and the IC50 values is the leakage and 
passive diffusion of loaded liposomes could be different for FC and doxorubicin. 
Doxorubicin loading efficiency has been shown in Fig 2.3, demonstrating the low drug 
release rate.  
Hydrophobicity is another factor that leads to a difference in internalization. It has 
been shown that hydrophobic liposomes are more susceptible to phagocytosis than their 
hydrophilic counterparts. 58 Here, the IC50 values are remarkably influenced by 
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hydrophobicity. For modifications C, I, and L, which show mismatches between 
internalization of FC encapsulated liposomes and zeta potentials, these differences can be 
explained by hydrophobicity. All three modifications demonstrate higher surface tensions, 
resulting in increased hydrophobicity.  Most modifications have lower IC50 values than 
unmodified liposomes when comparing similar macrophage activations, indicating 
improvement of cytotoxicity. This result shows that the arginine derivations improve 
liposomes’ ability of taking up by macrophages and deliver drugs more efficiently and 
effectively.   
 
2.5 Conclusions 
Here, liposomes with surface modifications were studied for their ability to enhance 
drug delivery. Liposomes were modified with arginine derivatives. These modifications had 
no influence on particle size and drug loading efficiency. Differences were observed on the 
measured zeta potentials, which impacts internalization by macrophages. Cellular uptake of 
the liposomes was found to be dependent upon macrophage phenotype and surface 
modifications. There were also differences in trends between internalization of liposomal FC 
and the IC50 of liposomal doxorubicin, which were attributed to changes in the ability of 
doxorubicin to escape the endosome. This work demonstrates the importance of investigating 
how liposomes interact with different macrophage types and the ability to preferentially 
deliver drugs to specific macrophage phenotypes. The results claims that liposomes modified 
with arginine derivation are promising efficient nanoparticle vehicles for delivery to 
macrophages. 
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